Design Therapeutics
DSGN
97 hedge funds and large institutions have $244M invested in Design Therapeutics in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 43 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
9% more capital invested
Capital invested by funds: $223M → $244M (+$21.1M)
1% more funds holding
Funds holding: 96 → 97 (+1)
0.16% more ownership
Funds ownership: 69.17% → 69.32% (+0.16%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
30% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 43
67% less call options, than puts
Call options by funds: $12K | Put options by funds: $36K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$9.56M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.13M |
| 3 |
Goldman Sachs
New York
|
+$898K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$859K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$817K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.12M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.96M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.83M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.51M |
| 5 |
BlackRock
New York
|
-$1.17M |
DSGN Hedge Fund Activity: Q2 2023 in Review
97 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q2 2023, worth a combined $244M — up 9.5% from $223M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new DSGN positions and 9 closed out — a net gain of 1 holder — while 30 added to existing stakes and 43 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $9.56M. The largest seller was Millennium Management, cutting an estimated $3.12M.
- 97 institutional investors held Design Therapeutics (DSGN) as of Q2 2023, up from 96 in Q1 2023.
- Funds reported $244M of Design Therapeutics stock for Q2 2023, up 9.5% quarter-over-quarter.
- 10 funds opened new Design Therapeutics positions in Q2 2023 and 9 closed out, a net change of +1 holder.
- The largest Design Therapeutics buyer in Q2 2023 was RTW Investments, an estimated $9.56M added.
- The largest Design Therapeutics seller in Q2 2023 was Millennium Management, an estimated $3.12M sold.
Based on aggregated 13F filings for Q2 2023.